Related Experiment Video

Updated: Oct 4, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K

LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer

Ramona Rudalska1, Jule Harbig1, Marteinn T Snaebjornsson2,3

  • 1Department of Medical Oncology and Pneumology, University Hospital Tuebingen, Tuebingen, Germany.

Nature Cancer
|February 5, 2022
PubMed

Insights

Pharmacologically induced lipotoxicity offers a novel strategy for treating liver cancer (HCC). Combining LXR agonists with Raf inhibitors creates synthetic lethality, overcoming therapy resistance by inducing toxic fatty acid accumulation.

Area of Science:

  • Oncology
  • Metabolic pathways
  • Hepatocellular carcinoma (HCC)

Background:

  • Cancer metabolic plasticity limits molecular therapies.
  • Targeting metabolic pathways in hepatocellular carcinoma (HCC) requires novel strategies.

Purpose of the Study:

  • To investigate pharmacologically induced lipotoxicity as a therapeutic strategy for HCC.
  • To explore the synthetic lethality between LXRα-induced lipogenesis and Raf-1 inhibition in HCC.

Main Methods:

  • Utilized genetically engineered and nonalcoholic steatohepatitis-induced HCC mouse models.
  • Employed xenograft models of human HCC.
  • Investigated the interaction between Raf-1, SCD1, and the effect of DFG-out Raf inhibitors.

Main Results:

  • LXRα activation and Raf-1 inhibition induce synthetic lethality in HCC.
  • Disruption of Raf-1/SCD1 interaction blocks fatty acid desaturation, causing lethal lipotoxicity.
  • Combination therapy with LXR agonists and Raf inhibitors was well-tolerated and effective in preclinical HCC models, overcoming resistance.

Conclusions:

  • Pharmacologically induced lipotoxicity is a promising therapeutic approach for liver cancer.
  • Targeting metabolic vulnerabilities, specifically fatty acid metabolism, offers a new avenue for HCC treatment.
  • Combination therapy demonstrates potential for overcoming treatment resistance in HCC.

More Related Videos

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy07:20

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy

Published on: January 31, 2025

695
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.2K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.5K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.0K
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
2.9K